NCT03945981 - Rapid Test and Treat Dolutegravir Plus Lamivudine Study in Newly Diagnosed Human Immunodeficiency Virus (HIV)-1 Infected Adults | Biotech Hunter

Enrollment

131

Participants

Timeline

Start Date

July 2, 2019

Primary Completion Date

April 29, 2020

Study Completion Date

October 20, 2020

Conditions

HIV Infections

Interventions

DRUG

Dolutegravir + Lamivudine FDC

Dolutegravir + Lamivudine FDC is available as white oval film-coated tablets which are packed in high density polyethylene (HDPE) bottles with induction seals and child-resistant closures. Each 60 milliliter (mL) bottle contains 30 tablets

Trial Locations (16)

28078

GSK Investigational Site, Huntersville

30030

GSK Investigational Site, Decatur

31405

GSK Investigational Site, Savannah

32803

GSK Investigational Site, Orlando

32806

GSK Investigational Site, Orlando

33136

GSK Investigational Site, Miami

33334

GSK Investigational Site, Oakland Park

34982

GSK Investigational Site, Ft. Pierce

35294

GSK Investigational Site, Birmingham

55415

GSK Investigational Site, Minneapolis

63108

GSK Investigational Site, St Louis

75246

GSK Investigational Site, Dallas

77401

GSK Investigational Site, Bellaire

78705

GSK Investigational Site, Austin

90036

GSK Investigational Site, Los Angeles

92262

GSK Investigational Site, Palm Springs